Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.